Array
(
[0] => Document type
[1] => Type of approval report
[2] => Type of article
[3] => Type of book chapter
[4] => Type of public document
[5] => Type of synthetic document
[6] => Session/Presentation/Abstract
[7] => Code
[8] => Chapter number
[9] => Title
[10] => Original language
[11] => Header
[12] => Reference number
[13] => Additional title
[14] => Translation language
[15] => Authors
[16] => Book title
[17] => Book authors
[18] => Publisher
[19] => Organism
[20] => Marketing authorisation holder
[21] => Journal name
[22] => Source
[23] => Publication date
[24] => Marketing authorisation date
[25] => Publication Number
[26] => Last revision-Suppl. date
[27] => Journal volume
[28] => Journal issue
[29] => Start page
[30] => End page
[31] => Meeting title
[32] => Abstract
[33] => Abstract Derwent
[34] => Area / Topic
[35] => Product / Class
[36] => Focus on Servier product
[37] => Target
[38] => Study acronym
[39] => Publication princeps
[40] => R&D Study
[41] => Study number
[42] => Supplementary information
[43] => Date of entry into force
[44] => Deadline for comments
[45] => Regulatory version
[46] => Repeals/Repealed by
[47] => Retention period
[48] => Application Date
[49] => Application Number
[50] => Priority date
[51] => Priority Number
[52] => Keywords
[53] => Usage
[54] => eCTD Ready
[55] => Contains/Contained in
[56] => See also
[57] => Related reports
[58] => Appears in
[59] => Comments
[60] => Private comments
[61] => Status
[62] => Order date
[63] => Other availability
[64] => Person in charge
[65] => Notes
[66] => Date_indexation
[67] => Chapter title
[68] => Nb of consultations
[69] => Archive names
[70] => Num_document
)
Array
(
[0] => (EPOC1201)"
[1] => ,,,,,TRINCOT Anne,18016.pdf,24/11/2016,V645 : TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.,32,,137816
[2] => ,,,,American Society of Clinical Oncology (ASCO),,J Clin Oncol,,2016,,,,34,suppl,,,52nd Annual Meeting of the American Society of Clinical Oncology (ASCO),,,Colorectal cancer;Clinical trials data;Adverse drug reactions,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,RECOURSE,,,,,,,,,,,,,,,,,,,,,,,,,,TRINCOT Anne,,27/05/2016,e15021 : Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.,19,,131511
[3] => ,,Colorectal cancer;Adverse drug reactions,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,6/07/2018,,PINJON-CASU Emmanuelle,,6/07/2018,Biweekly administration of TAS-102 for neutropenia prevention in patients with colorectal cancer.,14,,148392
[4] => ,,Colorectal cancer;Pre-clinical data,Trifluridine+Tipiracil hydrochloride;Programmed cell-death protein 1 (PD-1) inhibitors,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,23829.pdf,28/03/2018,J-3080 : Efficacy of trifluridine/tipiracil plus anti-mouse PD-1 antibody combination on mouse colorectal cancer model.,9,,146720
[5] => ,,Gastric cancer,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,mdy432.027.pdf,3/12/2018,175P - Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS).,11,,150517
[6] => ,,Lievre A,,,,,,HGOD,,,,,,26,8,1,8,,,,Gastric cancer,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,13/11/2019,What is changing in practice for gastric cancer?.,31,,155685
[7] => ,,Oncology;Clinical trials data,Trifluridine+Tipiracil hydrochloride,,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRINCOT Anne,,11/07/2016,The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution
[8] => ,Ann Biomed Eng,,,,,Nijenhuis CM;Schellens JH;Beijnen JH,,,,,,,,2016,,,,,0360-2532
[9] => ,English,,,,,Argiles G;Yoshino T;Ohtsu A;Mayer RJ;Winkler R;Amellal N;Fougeray R;Kanehisa A;Van Custem E,,,,Servier,,,,,,,,,,,,2018 Gastrointestinal Cancers symposium,,,Colorectal cancer;Clinical trials data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,RECOURSE,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,1/02/2018,,10,,145755
[10] => ,English,,,,,Arita S;Shirakawa T;Matsushita Y;Kumagai H;Hirano G;Makiyama A;Shibata Y;Tamura S;Kusaba H;Baba E,,,,Japanese Society of Medical Oncology (JSMO),,Ann Oncol,,2015,,,,26,suppl 7,,,13th Annual meeting of the Japanese Society of Medical Oncology,,,Colorectal cancer;Clinical trials data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRINCOT Anne,,1/02/2016,Trifluridine-tipiracil for multidrug-resistant advanced colorectal cancer: A multicenter retrospective study
[11] => ,English,,,,,Hollebecque A;Calvo A;André T;Argiles G;Cervantes A;Leger C;Valette A;Amellal N;Fougeray R;Tabernero J,,,,Servier IDRS,,,,,,,,,,,,2018 Gastrointestinal Cancers symposium,,,Colorectal cancer;Clinical trials data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,5/02/2018,,20,,145788
[12] => ,English,,,,,Kuboki Y;Yoshino T;Yamazaki K;Nishina T;Komatsu Y;Baba H;Tsuji A;Yamaguchi K;Muro K;Ohtsu A,,,,,,European Journal of Cancer
[13] => ,English,,,,,Matsuoka K;Nakagawa F;Kobunai T;Takechi T,,,,Taiho Pharmaceutical,,Oncotarget,,2018,,,,9,17,13438,13450,,Trifluridine/tipiracil (FTD/TPI or TFTD
[14] => ,English,,,,,Price TJ;Taieb J;Falcone A;Seitz JF;Wyrwicz L;Becquart M;Moreno Vera SR;Mounedji N;Van Custem E,,,,Servier,,,,,,,,,,,,2018 Gastrointestinal Cancers symposium,,,Colorectal cancer,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,NCT03306394,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,5/02/2018,,18,,145789
[15] => ,English,,,,,Sun W;Rosen LS;Rasco DW;Yoshida K;Seraj J;Shapiro G;Cleary JM,,,,,,,,2016,,,,,,,,2016 Gastrointestinal Cancers symposium,,,Oncology;Pharmacokinetic data;Clinical trials data;Clinical pharmacokinetic data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRINCOT Anne,,1/02/2016,,3,,126862
[16] => ,English,,,,,Sun W;Rosen LS;Rasco DW;Yoshida K;Seraj J;Shapiro G;Cleary JM,,,,,,J Clin Oncol,,2016,,,,34,suppl 4S,751,,2016 Gastrointestinal Cancers symposium,,,Oncology;Pharmacokinetic data;Clinical trials data;Clinical pharmacokinetic data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,TRINCOT Anne,,7/10/2015,An Open-Label
[17] => ,English,,,,,Yoshino T;Oki E;Nozawa H;Eguchi Nakajima T;Taniguchi H;Morita S;Takenaka N;Ozawa D;Shirao K;TRUSTY Study Group,,,,Taiho Pharmaceutical,,,,,,,,,,,,2018 Gastrointestinal Cancers symposium,,,Colorectal cancer,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,TRUSTY,,,JapicCTI-173618,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,5/02/2018,,18,,145790
[18] => ,English,,,,,Yuki S;Komatsu Y;Yagisawa M;Tsuji Y;Harada K;Hatanaka K;Okuda H;Hosokawa A;Ogawa K;Furukawa K;Minami S;Ishiguro A;Honda T;Ohta T;Dazai M;Eto K;Sasaki T;Nakajima J;Sakamoto N;Sakata Y,,,,,,,,2017,,,,,,,,42nd congress of the European Society for Medical Oncology (ESMO),,,Colorectal cancer;Clinical data,Trifluridine+Tipiracil hydrochloride,Focus on Servier product,,,,,,,,,,,,,,,,,,,,,,,,,,,,PINJON-CASU Emmanuelle,,14/02/2018,,13,,145977
[19] => ."
[20] => 2016
[21] => ;Imam H;Tang PA;Monzon J;Li H;Sun G;Ezeife D;Parimi S;Dowden S;Tam VC"
[22] => ;Usami E;Teramachi H;Yoshimura T"
[23] => AN - 31848317"
[24] => AN - PMC6527138"
[25] => AV - EMBASE"
[26] => CI: 4%
[27] => CONCLUSION: Biweekly administration without a change in the drug dose intensity was associated with reduced neutropenia in patients with mCRC. The effects and adverse events of TAS-102 were associated with concomitant drug administration
[28] => Conclusion The aflibercept-chemotherapy regimen is a therapeutic option in chemorefractory patients beyond second-line therapy
[29] => Conclusion: The treatment with trifluridin/tipiracil we evaluate positively. Trifluridin/tipiracil is an integral part of treatment in
[30] => Conclusions Testing mCRC patients for RAS status and administering EGFR inhibitors only to patients with RAS wild-type tumors is a more cost-effective strategy than treating all patients without testing. The treatment of mCRC is becoming more personalized
[31] => Conclusions: Patients’ beliefs in the necessity of their oral medication were affected only by a permanent drug stoppage. Symptom severity
[32] => Congress document
[33] => DP - 2016 May 17"
[34] => Dr Jordi Bruix then demonstrated the possibility of using regorafenib as a second-line therapy in patients with hepatocellular carcinoma (HCC) who have progressed following sorafenib therapy."
[35] => Drug Administration between January 2011 and April 2017. Results from studies evaluating food effect
[36] => Fluorouracil still constitutes the backbone of metastatic colorectal cancer treatment; fluorouracil
[37] => However
[38] => Journal article
[39] => LP - 1055"
[40] => LP - 1071"
[41] => LP - 26"
[42] => LP - 3075"
[43] => LP - 3990"
[44] => La radiothérapie en conditions stéréotaxiques s’est largement développée ces dernières années. De nombreux résultats ont été publiés sur de multiples localisations. Afin de clarifier les évidences parmi toutes les publications
[45] => Methods A systematic review of full economic evaluations comparing RAS testing with no testing was performed for articles published in English between 2000 and 2018. Study quality was assessed using the Quality of Health Economic Studies scale
[46] => Methods mCRC patients treated with aflibercept beyond second-line therapy were included. Objective response rate
[47] => Objectives We aimed to review the cost-effectiveness of RAS testing in mCRC patients before anti-EGFR therapy and to assess how well economic evaluations adhere to guidelines.
[48] => PATIENTS AND METHODS: The medical records of 41 patients with CRC who received TAS-102 between October 2014 and June 2017 at the Fukuoka University Hospital were retrospectively reviewed. Response rate
[49] => Patients and Methods: Tumor tissues from 50 consecutive adult patients with metastatic solid cancer that is refractory to standard of care
[50] => Patients and methods: A total of 18 patients with refractory metastatic colorectal cancer
[51] => QALY. Based on the CONCUR trial data
[52] => RESULTS: Both PFS and OS were significantly higher with TAS-102 plus bevacizumab combination therapy. Biweekly administration (7.1%) was associated with significantly less neutropenia compared to normal administration (44.4%). DCR with biweekly administration was better than that with normal administration
[53] => Results 130 patients were included. Median OS and PFS were 7 (95% CI [6-9]) and 3 months (95% CI [2-3])
[54] => Results Six economic evaluations (2 cost-effectiveness analyses
[55] => Results from 3 phase 1 trials and the phase 3 RECOURSE trial"
[56] => Results from 3 phase 1 trials and the phase 3 RECOURSE trial."
[57] => Results: At the time of this analysis
[58] => Results: Over the initial 12 weeks beliefs about the necessity of oral medications increased
[59] => Results: Patients’ median age was 56 years
[60] => Since decades
[61] => Standardanalysen Optimierung der Therapie des Kolonkarzinoms"
[62] => TAS-102 and regorafenib even when the predictive value of the tumor response measured using RECIST is not clear."
[63] => TFTD adherence in the first cycle was associated with prior regimens Ž 4. Conclusions: The high frequency of treatment-related gastrointestinal disorder is the main factor affecting adherence to TFTD. Intensive supportive care in the management of these symptoms could assist adequate adherence to TFTD in mCRC patients."
[64] => XELOX) are chemotherapy protocols established as treatments producing similar outcomes. Actual treatment involves these chemotherapy protocols in combination with new molecular targeted drugs: bevacizumab and aflibercept (anti-vascular endothelial growth factor monoclonal antibody) and cetuximab and panitumumab (anti-epidermal growth factor receptor monoclonal antibody for patients with wild type KRAS) which confer significant survival benefits in select patients as first- or second-line therapies. The factors affecting the decisions for one treatment overother are related to the patient and toxicity drug. Finally
[65] => advanced/recurrent colorectal cancer was investigated. Patients and methods: Between August 2014 and May
[66] => after 3 cycles of treatment
[67] => against these pathways has already shown clinical efficacy that has led to their FDA approval in the treatment of
[68] => bevacizumabe ou aflibercepte: experiência clínica
[69] => colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond."
[70] => colorretal metastático previamente tratados com
[71] => combination plus either irinotecan (FOLFIRI)
[72] => examined by univariate and multivariate analyses. Results: In 41 patients
[73] => field of GI tumors
[74] => good ECOG performance status) could be candidates for further therapies such as regorafenib and TAS-102. Regarding the future
[75] => head and neck cancer. This review will summarize the current clinical progress of modern immunotherapy in the
[76] => in 10 patients (24.4%)
[77] => karcinomu"
[78] => medical care and will turn to pharmacists with questions about these new drugs and their applicability to their tumor type"
[79] => metastatic colorectal cancer (mCRC) patients. Methods: We retrospectively compared systemic chemotherapy outcomes between elderly (75 years) and adult (74 years) patients with mCRC who were treated between January 2007 and December 2012 at Hiroshima University Hospital and analyzed the outcomes of elderly patients after treatment with single agent oral 5-fluorouracil chemotherapy (oral FC) or intravenous combination chemotherapy (IV CC) as the first-line regimen. Results: A total of 140 patients with mCRC were enrolled. The median age of adult patients was 60 years
[80] => negatively regulate T cell activation via distinct mechanisms. Immune checkpoint blockade with antibodies directed
[81] => neutropenia. The median overall survival times in the absent
[82] => of GI malignancies. Immunotherapy is a novel treatment strategy that is emerging as an effective and promising
[83] => on the market of numerous drugs
[84] => optimal sequencing of these options to maximize their proportional OS benefit for patients is of utmost importance; it remains a topic of continued investigation. Here
[85] => orally
[86] => order to favour compliance."
[87] => patient due to thrombocytopenia. Median of PFS was 3
[88] => patients with refractory metastatic colorectal cancer."
[89] => present with advanced
[90] => refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study"
[91] => refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study."
[92] => sequencing
[93] => several solid tumors including melanoma
[94] => survival results compared with placebo in refractory metastatic colorectal cancer (mCRC). In the phase III CORRECT study
[95] => the dose intensity divided by the initial dose (each in milligrams per square meter per week). Results: Patient characteristics were as follows: males/females
[96] => the two monoclonal antibodies blocking the programmed death-1 (PD-1) receptor
[97] => treatment option against several types of cancers. CTLA-4 and PD-1 are critical immune checkpoint molecules that
[98] => uni-institucional"
[99] => well as cisplatin
[100] => with better control of nausea and vomiting
)
Array
(
[0] => 20.7 vs 26.5 months; P = 0.65) and first-line progression-free survival (PFS) (median
[1] => 61 years (range
[2] => BSC was more cost-effective than regorafenib or TAS-102 at the willingnessto- pay threshold below $ 700
[3] => FTD
[4] => NRAS mutation analysis
[5] => OS
[6] => Parallel-Group Study of the Pharmacokinetics of Trifluridine as a Component of TAS-102 vs FTD Alone.
[7] => and 18 (43.9%) did not experience
[8] => and 2 combined cost-effectiveness and cost-utility analyses) were included. All studies were of good quality and adopted the perspective of the healthcare system/payer; accordingly
[9] => and interference of medications with daily lives increased. Permanent stoppage of a medication predicted significant declines in beliefs about its necessity over time. Male patients
[10] => and nutritional status.
[11] => and patient sex affected patients’ beliefs about their concerns with their medications
[12] => and progression-free survival (PFS) were assessed.
[13] => and severe groups were 120 days (95% confidence interval [CI]
[14] => drug-drug interactions
[15] => hépatiques
[16] => patients must be given expert and accurate advice
[17] => rates of nausea and vomiting were 52% and 24%
[18] => renal cell carcinoma
[19] => stable disease 38.5%
[20] => the biweekly regimen was associated with significantly prolonged PFS. By multivariate analysis
[21] => the therapeutic armamentarium for metastatic disease has increased significantly; 10 new drug approvals include targeted biologics and tyrosine kinase inhibitors. With this increase in options
[22] => the toxicity profiles were quite different between the two agents. Summary: Regorafenib and TAS-102 are approved for the management of refractory mCRC. Optimal treatment sequence for using these two novel agents is not defined yet. Safety profiles and patient’s condition should be considered before using these two agents in clinical settings. Further investigation is needed to identify the predictive biomarkers of both agents. These results will allow patients to benefit more from regorafenib and TAS-102."
[23] => this recommendation review was written. Voluntarily
[24] => were evaluated.
[25] => which are now approved by the U.S. Food and Drug Administration for the treatment of renal cell carcinoma
[26] => who continues treatment
[27] => with 52% having either breast
[28] => 108th Annual Meeting of the American Association for Cancer Research (AACR)
[29] => 7
[30] => 88
[31] => 9–4
[32] => Bando H;Doi T;Muro K;Yasui H;Nishina T;Yamaguchi K;Takahashi S;Nomura S;Kuno H;Shitara K;Sato A;Ohtsu A
[33] => Buchler T;Hornova J
[34] => Case report
[35] => Case report;Review
[36] => Clinical practice guidelines
[37] => Clinical trial
[38] => Colorectal cancer
[39] => Colorectal cancer;Clinical data
[40] => Colorectal cancer;Clinical trials data
[41] => Colorectal cancer;Clinical trials data;Adverse drug reactions
[42] => Comment
[43] => Congress abstract
[44] => Congress abstract;Case report
[45] => Congress abstract;Clinical trial
[46] => Congress abstract;Congress abstract
[47] => Congress abstract;Meta-analysis
[48] => Congress abstract;Non-clinical study
[49] => Editorial
[50] => Letter
[51] => Letter;Case report
[52] => Meta-analysis
[53] => Meta-analysis;Review
[54] => News
[55] => Nogueira Fogace R;Senna Leite LA;Ribeiro Nebuloni D;Mendonça Bariani G;Capareli F;Soares Da Silva Rocha L;Gehm Hoff PM;Giollo Rivelli T;Riechelmann RP
[56] => Non-clinical study
[57] => Oncology
[58] => Oncology;Gastric cancer
[59] => Oncology;Regulatory
[60] => Review
[61] => Review;Case report
[62] => Review;Clinical practice guidelines
[63] => Review;Meta-analysis
[64] => Virchow I;Herold T;Wiesweg M;Kasper S
)
Array
(
[0] => 0.201–0.974; p = 0.042). Conclusion: In patients with advanced/recurrent colorectal cancer
[1] => 22 instances)
[2] => deoxyuridine monophosphate levels in MKN45/5FU cells after 24-h FTD treatment were 3.0-fold higher than those in parental cells
[3] => partial remission
[4] => 2016
[5] => 2017
[6] => 2019
[7] => American Society of Clinical Oncology (ASCO)
[8] => Ann Biomed Eng
[9] => Czech
[10] => Dutch
[11] => English
[12] => French
[13] => German
[14] => Hungarian
[15] => Italian
[16] => Japanese
[17] => Oncology;Clinical pharmacology
[18] => Portuguese
[19] => S392
[20] => Spanish
[21] => Trifluridine+Tipiracil hydrochloride
[22] => Turkish
)
Array
(
[0] => FTD/TPI is a promising chemotherapeutic agent against gastric cancers recurring following 5-FU therapy. "
[1] => 33
[2] => 35
)
Array
(
[0] => FTD/TPI is a promising chemotherapeutic agent against gastric cancers recurring following 5-FU therapy. "
[1] => 33
[2] => 35
)
Array
(
[0] => Journal article
[1] =>
[2] =>
[3] =>
[4] =>
[5] =>
[6] =>
[7] => PE0120912
[8] =>
[9] => A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA
[10] => English
[11] =>
[12] =>
[13] =>
[14] =>
[15] => Emura T;Suzuki N;Yamaguchi M;Ohshimo H;Fukushima M
[16] =>
[17] =>
[18] =>
[19] =>
[20] =>
[21] => Int J Oncol
[22] =>
[23] => 2004
[24] =>
[25] =>
[26] =>
[27] => 25
[28] => 3
[29] => 571
[30] => 578
[31] =>
[32] => TAS-102 is a new antimetabolite agent composed of a alpha, alpha, alpha-trifluorothymidine (FTD; 1 M) and thymidine phosphorylase inhibitor (TPI; 0.5 M). Here, we investigated the antitumor effect and mechanism of TAS-102 against 5-FU, or FdUrd, resistant human cancer cell lines. The respective tumor growth inhibition rate of orally administered FTD against 5-FU-resistant NUGC-3 was about 70% at a dose level of 200 mg/kg/day; this value was comparable to that against the parental NUGC-3. On the other hand, the tumor inhibition rates of 5-FU, FdUrd, and TS-1 against 5-FU-resistant NUGC-3 were lower than those against parental NUGC-3. Similar observations were made in an FdUrd-resistant human colorectal cancer cell line (DLD-1). TAS-102 was also effective in 5-FU-less sensitive human pancreatic cancer cell lines (PAN-12 and BxPC-3) and human esophagus cancer (T.T.) when compared with 5-FU or UFT. Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition. We then examined the effects of FTD on DNA at the cellular level. After treatment with FTD or FdUrd, the DNA fragmentation pattern was examined using filter elution and in situ nick translation. Treatment with FTD for 2 h resulted in marked DNA fragmentation. When the tumor cells were treated with FTD for 72 h or with FdUrd for 2 or 72 h, only a small amount of DNA fragmentation was observed, and the appearance of the tumor cells did not differ markedly from that of untreated cells. Moreover, the DNA fragmentation rate in the TAS-102 treatment group was significantly higher than that in the control group in vivo. These results suggest that when tumor cells are exposed to high concentrations of FTD for short periods of time, FTD manifests its antitumor activity primarily through the induction of DNA fragmentation after FTD incorporation into the DNA. We conclude that TAS-102 is expected to manifest antitumor effects against 5-FU-resistant tumors that are similar to those exerted in 5-FU-sensitive tumors.
[33] =>
[34] => Oncology;Fixed-dose combination;Pharmacological data
[35] => Trifluridine+Tipiracil hydrochloride
[36] => Focus on Servier product
[37] =>
[38] =>
[39] =>
[40] =>
[41] =>
[42] =>
[43] =>
[44] =>
[45] =>
[46] =>
[47] =>
[48] =>
[49] =>
[50] =>
[51] =>
[52] =>
[53] => CTDS95005
[54] => Yes
[55] =>
[56] =>
[57] =>
[58] =>
[59] =>
[60] =>
[61] =>
[62] =>
[63] =>
[64] => TRINCOT Anne
[65] => 15289858.pdf
[66] => 22/07/2015
[67] => A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
[68] => 16
[69] =>
[70] => 120912
)